Insider Trading Alert - TSLA, REGN And GPRE Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Aug. 6, 2014, 78 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $704.00 to $5,552,766.23.

Highlighted Stocks Traded by Insiders:

Tesla Motors (TSLA) - FREE Research Report

Musk Kimbal, who is Director at Tesla Motors, sold 4,287 shares at $234.46 on Aug. 6, 2014. Following this transaction, the Director owned 166,435 shares meaning that the stake was reduced by 2.51% with the 4,287-share transaction.

The shares most recently traded at $249.50, up $15.04, or 6.03% since the insider transaction. Historical insider transactions for Tesla Motors go as follows:

  • 4-Week # shares sold: 4,811
  • 12-Week # shares sold: 4,811
  • 24-Week # shares sold: 4,811

The average volume for Tesla Motors has been 5.5 million shares per day over the past 30 days. Tesla Motors has a market cap of $29.6 billion and is part of the consumer goods sector and automotive industry. Shares are up 65.48% year-to-date as of the close of trading on Wednesday.

Tesla Motors, Inc. designs, develops, manufactures, and sells electric vehicles and electric vehicle powertrain components. Currently, there are 5 analysts who rate Tesla Motors a buy, 1 analyst rates it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TSLA - FREE

TheStreet Quant Ratings rates Tesla Motors as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, weak operating cash flow and poor profit margins. Get the full Tesla Motors Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Regeneron Pharmaceuticals (REGN) - FREE Research Report

Goldstein Joseph L, who is Director at Regeneron Pharmaceuticals, sold 2,000 shares at $331.20 on Aug. 6, 2014. Following this transaction, the Director owned 8,000 shares meaning that the stake was reduced by 20% with the 2,000-share transaction.

The shares most recently traded at $339.12, up $7.92, or 2.34% since the insider transaction. Historical insider transactions for Regeneron Pharmaceuticals go as follows:

  • 4-Week # shares bought: 255
  • 4-Week # shares sold: 1,000
  • 12-Week # shares bought: 255
  • 12-Week # shares sold: 1,000
  • 24-Week # shares bought: 255
  • 24-Week # shares sold: 2,000

The average volume for Regeneron Pharmaceuticals has been 868,900 shares per day over the past 30 days. Regeneron Pharmaceuticals has a market cap of $32.9 billion and is part of the health care sector and drugs industry. Shares are up 23.78% year-to-date as of the close of trading on Wednesday.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company has a P/E ratio of 94.7. Currently, there are 7 analysts who rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on REGN - FREE

TheStreet Quant Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Regeneron Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Green Plains (GPRE) - FREE Research Report

Bleyl Carl S, who is EVP of Ethanol Marketing at Green Plains, sold 46,307 shares at $40.11 on Aug. 6, 2014. Following this transaction, the EVP of Ethanol Marketing owned 60,821 shares meaning that the stake was reduced by 43.23% with the 46,307-share transaction.

The shares most recently traded at $40.14, up $0.03, or 0.07% since the insider transaction. Historical insider transactions for Green Plains go as follows:

  • 4-Week # shares sold: 15,000
  • 12-Week # shares sold: 19,374
  • 24-Week # shares sold: 59,374

The average volume for Green Plains has been 1.0 million shares per day over the past 30 days. Green Plains has a market cap of $1.5 billion and is part of the basic materials sector and chemicals industry. Shares are up 105.06% year-to-date as of the close of trading on Wednesday.

Green Plains Inc. produces, markets, and distributes ethanol in the United States. The company operates through four segments: Ethanol Production, Corn Oil Production, Agribusiness, and Marketing and Distribution. The stock currently has a dividend yield of 0.4%. The company has a P/E ratio of 13.9. Currently, there are 5 analysts who rate Green Plains a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on GPRE - FREE

TheStreet Quant Ratings rates Green Plains as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and attractive valuation levels. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Green Plains Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

GE Confirms $11.1 Billion Transportation Merger With Wabtec

GE Confirms $11.1 Billion Transportation Merger With Wabtec

Gold Prices Look 'Rich' at Current Levels - Here's What Could Change That

Gold Prices Look 'Rich' at Current Levels - Here's What Could Change That

Dow Rises Sharply as U.S.-China Trade Tensions Thaw

Dow Rises Sharply as U.S.-China Trade Tensions Thaw

To Win at Trade the U.S. Must Act and Behave Like China

To Win at Trade the U.S. Must Act and Behave Like China

Video: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Video: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron